Immunicum AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.03.24	Mendus to present NK cell program progress at the Innate Killer Summit (GlobeNewswire)
15.03.24	Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3 (GlobeNewswire)
15.03.24	The exercise period for warrants of series TO3 commences today (GlobeNewswire)
12.03.24	Mendus provides business update and outlook for vididencel program (GlobeNewswire)
27.02.24	Mendus to participate in upcoming industry conferences (GlobeNewswire)
23.02.24	Mendus to hold Business Update event on March 12 (GlobeNewswire)
14.02.24	Mendus AB Year-end Report for 2023 (GlobeNewswire)
09.02.24	Invitation to presentation of Mendus’ year-end report for 2023 (GlobeNewswire)
08.01.24	Mendus to participate in several investor and industry conferences in January (GlobeNewswire)
22.12.23	Mendus announces clinical pipeline update (GlobeNewswire)
13.12.23	Mendus AB: REPORT FROM THE EXTRAORDINARY GENERAL MEETING OF MENDUS AB (PUBL) ON 13 DECEMBER 2023 (GlobeNewswire)
11.12.23	Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023 (GlobeNewswire)
06.12.23	Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML (GlobeNewswire)
05.12.23	Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6 (GlobeNewswire)
04.12.23	Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023 (GlobeNewswire)
17.11.23	Mendus Announces Nomination Committee for the 2024 Annual General Meeting (GlobeNewswire)
13.11.23	NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL) (GlobeNewswire)
09.11.23	Mendus AB Interim Report January – September 2023 (GlobeNewswire)
06.11.23	Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023 (GlobeNewswire)
03.11.23	Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal (GlobeNewswire)
02.11.23	Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data (GlobeNewswire)
26.10.23	Mendus to participate in several investor and industry conferences in November and to host investor webcast and lunch on November 9 (GlobeNewswire)
28.09.23	Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC (GlobeNewswire)
21.09.23	Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23 (GlobeNewswire)
08.09.23	Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML) (GlobeNewswire)
06.09.23	Mendus Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference in September (GlobeNewswire)
04.09.23	Mendus to participate in multiple investor and industry conferences in September (GlobeNewswire)
31.08.23	Change in number of shares and votes in Mendus AB (publ) (GlobeNewswire)
29.08.23	Mendus AB (publ) Interim Report January – June 2023 (GlobeNewswire)
16.08.23	Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies (GlobeNewswire)
28.07.23	Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue (GlobeNewswire)
11.07.23	Mendus publishes prospectus regarding previously announced rights issue and directed issue (GlobeNewswire)
10.07.23	Mendus AB: Report from the extraordinary general meeting of Mendus AB (publ) on 10 July 2023 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’243.50	1.26 %	K V
Novartis	92.57	1.10 %	K V
Roche Hldg G	253.80	1.08 %	K V
Geberit	521.80	1.01 %	K V
Sonova Hldg	306.80	0.92 %	K V
Kuehne+Nagel Int	208.20	0.10 %	K V
Swiss Life Hldg	727.60	0.06 %	K V
UBS Group	28.15	0.04 %	K V
Holcim	89.88	0.02 %	K V
CieFinRichemont	117.25	-0.34 %	K V

Nachrichten zu Immunicum AB

Aktien Top/Flop

Meistgelesene Nachrichten